ClinicalTrialsFinder
RecruitingNot ApplicableNCT06892158

Massage Impact on Sleep in Pediatric Oncology

Massage Impact on Sleep in Hospitalization for Pediatric Oncology and Stem Cell Transplant Patients

Sponsor

Children's Hospital of Philadelphia

Enrollment

70 participants

Start Date

Jan 23, 2025

Study Type

INTERVENTIONAL

Conditions

CancerAcute Myeloid LeukemiaChemotherapy EffectPediatric CancerAcute Lymphoblastic Leukemia, PediatricHematopoietic Stem Cell Transplantation (HSCT)

Summary

This study aims to determine the impact of massage therapy for pediatric patients receiving intensive chemotherapy or stem cell transplant (SCT).

Eligibility

Min Age: 12 YearsMax Age: 21 Years

Inclusion Criteria4

  • Diagnosis of cancer, such as acute myeloid leukemia (AML) or relapsed acute lymphoblastic leukemia (rALL) OR admitted to receive autologous or allogeneic HSCT for any indication
  • Expected to be an inpatient for at least 21 days
  • Aged 12 to 21 years at enrollment.
  • Inpatient at Children's National or Children's Hospital of Philadelphia (CHOP).

Exclusion Criteria3

  • Cognitive impairment sufficient to preclude completing questionnaires appropriately
  • Insufficient knowledge of English or Spanish that would prohibit completing the study instruments
  • Previous enrollment

Interventions

OTHERMassage therapy

Participants in IA will receive a 20-30-minute massage five days per week for 21 days.

OTHERStandard of care

Institutional standard of care treatment

Locations(2)

Children's National Hospital

Washington D.C., District of Columbia, United States

Children's Hospital of Philadelphia

Philadelphia, Pennsylvania, United States

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT06892158

Related Trials

MYELOMATCH: A Screening Study to Assign People With Myeloid Cancer to a Treatment Study or Standard of Care Treatment Within myeloMATCH (MyeloMATCH Screening Trial)

NCT05564390331 locations

Testing the Effects of Novel Therapeutics for Newly Diagnosed, Untreated Patients With High-Risk Acute Myeloid Leukemia (A MyeloMATCH Treatment Trial)

NCT05554406216 locations

Testing the Combination of an Anti-Cancer Drug, Iadademstat, With Other Anti-Cancer Drugs (Venetoclax and Azacitidine) for Treating AML

NCT065142614 locations

Comparing New Treatments for People With Newly Diagnosed Acute Myeloid Leukemia That Has an IDH2 Gene Change (A MyeloMATCH Treatment Trial)

NCT06672146112 locations

Comparing Cytarabine + Daunorubicin Therapy Versus Cytarabine + Daunorubicin + Venetoclax Versus Venetoclax + Azacitidine in Younger Patients With Intermediate Risk AML (A MyeloMATCH Treatment Trial)

NCT05554393175 locations